Wolfgang A Weber

Summary

Affiliation: University Hospital
Country: Germany

Publications

  1. pmc The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
    Dusan Milanović
    Department of Radiation Oncology, University Hospital Freiburg, Germany
    BMC Cancer 12:242. 2012
  2. doi [Molecular imaging in cancer therapy]
    W A Weber
    Nuklearmedizinische Klinik, Universitatsklinikum Freiburg, Deutschland
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53:810-7. 2010
  3. doi Quantitative analysis of PET studies
    Wolfgang A Weber
    Department of Nuclear Medicine, University Hospital Freiburg, Germany
    Radiother Oncol 96:308-10. 2010
  4. doi Assessing tumor response to therapy
    Wolfgang A Weber
    Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany
    J Nucl Med 50:1S-10S. 2009
  5. doi Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning
    Wolfgang A Weber
    Abteilung Nuklearmedizin, University of Freiburg, Hugstetterstrasse 56, 79106 Freiburg, Germany
    Nat Clin Pract Oncol 5:160-70. 2008
  6. ncbi 18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?
    Wolfgang A Weber
    University of Freiburg, Freiburg, Germany
    J Nucl Med 48:1580-2. 2007
  7. ncbi Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man
    Ambros J Beer
    Department of Nuclear Medicine, Lehrstuhl II für organische Chemie, Technische Universitat Munchen, Germany
    Clin Cancer Res 12:3942-9. 2006
  8. ncbi Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 46:2029-34. 2005
  9. ncbi Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, Munich, Germany
    Eur J Nucl Med Mol Imaging 34:1925-32. 2007
  10. ncbi PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression
    Ambros J Beer
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 47:763-9. 2006

Detail Information

Publications83

  1. pmc The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts
    Dusan Milanović
    Department of Radiation Oncology, University Hospital Freiburg, Germany
    BMC Cancer 12:242. 2012
    ..Therapy response was evaluated by measuring changes in tumor size and metabolic activity using 18F-FDG PET (Fluorodeoxyglucose - positron emision tomography) imaging...
  2. doi [Molecular imaging in cancer therapy]
    W A Weber
    Nuklearmedizinische Klinik, Universitatsklinikum Freiburg, Deutschland
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53:810-7. 2010
    ..Therefore, it is expected that molecular imaging will play an increasing role for guiding molecularly defined therapeutic interventions...
  3. doi Quantitative analysis of PET studies
    Wolfgang A Weber
    Department of Nuclear Medicine, University Hospital Freiburg, Germany
    Radiother Oncol 96:308-10. 2010
    ..Using such standardized acquisition protocols quantitative parameters of tumor metabolism or receptor status can be derived from tracer kinetic analysis and simplified approaches such as calculation of standardized uptake values (SUVs)...
  4. doi Assessing tumor response to therapy
    Wolfgang A Weber
    Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany
    J Nucl Med 50:1S-10S. 2009
    ..International guidelines and criteria for response assessment by (18)F-FDG PET in solid tumors are, therefore, eagerly awaited...
  5. doi Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning
    Wolfgang A Weber
    Abteilung Nuklearmedizin, University of Freiburg, Hugstetterstrasse 56, 79106 Freiburg, Germany
    Nat Clin Pract Oncol 5:160-70. 2008
    ..In this Review we discuss the technical features of PET/CT, its economic aspects within the health-care system, and its role in diagnosis, staging, restaging and treatment monitoring as well as radiation planning in patients with cancer...
  6. ncbi 18F-FDG PET in non-Hodgkin's lymphoma: qualitative or quantitative?
    Wolfgang A Weber
    University of Freiburg, Freiburg, Germany
    J Nucl Med 48:1580-2. 2007
  7. ncbi Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man
    Ambros J Beer
    Department of Nuclear Medicine, Lehrstuhl II für organische Chemie, Technische Universitat Munchen, Germany
    Clin Cancer Res 12:3942-9. 2006
    ..We have developed [18F]Galacto-RGD, a highly alpha(v)beta3-selective tracer for positron emission tomography (PET). Here, we show, in man, that the intensity of [18F]Galacto-RGD uptake correlates with alpha(v)beta3 expression...
  8. ncbi Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 46:2029-34. 2005
    ..We evaluated the temporal relationship between chemotherapy-induced changes in tumor glucose use and tumor size...
  9. ncbi Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, Munich, Germany
    Eur J Nucl Med Mol Imaging 34:1925-32. 2007
    ..To address this question we studied the time course of changes in tumor FDG-uptake in patients with locally advanced adenocarcinomas of the esophagogastric junction (AEG) treated with preoperative chemotherapy...
  10. ncbi PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression
    Ambros J Beer
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 47:763-9. 2006
    ..18)F-Galacto-RGD is a new tracer for PET imaging of alpha v beta3, a receptor involved in a variety of pathologic processes including angiogenesis and metastasis. Our aim was to study the dosimetry of (18)F-galacto-RGD in humans...
  11. doi Assessment of striatal dopamine D2/D3 receptor availability with PET and 18F-desmethoxyfallypride: comparison of imaging protocols suited for clinical routine
    Florian Amtage
    Department of Neurology, University Hospital Freiburg, Freiburg, Germany
    J Nucl Med 53:1558-64. 2012
    ..The present study was undertaken to define the optimal clinical scan protocol with regard to quantification accuracy and scan time...
  12. doi 123I-iodobenzamide SPECT is not an independent predictor of dopaminergic responsiveness in patients with suspected atypical parkinsonian syndromes
    Sabine Hellwig
    Department of Neurology, University Hospital Freiburg, Freiburg, Germany
    J Nucl Med 54:2081-6. 2013
    ..We investigated whether striatal dopamine D2/D3 receptor (D2R) binding assessed by (123)I-iodobenzamide SPECT is an independent predictor of dopaminergic responsiveness in patients with parkinsonism...
  13. doi Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin
    Rebecca A Dumont
    Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany
    J Nucl Med 54:762-9. 2013
    ..In addition, inhibition of the protein kinase mammalian target of rapamycin (mTOR) has been shown to sensitize various cancer cells to the effects of radiotherapy...
  14. pmc 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy
    Ken Herrmann
    Division of Surgical Oncology, University of California at Los Angeles, 10833 Le Conte Avenue, Rm 54 140 CHS, Los Angeles, CA 90095, USA
    Clin Cancer Res 18:2024-31. 2012
    ..We prospectively evaluated whether 2[18F]fluoro-2-deoxy-d-glucose ((18)F-FDG)-PET/computed tomographic (CT) imaging after the initial cycle of neoadjuvant therapy could predict overall survival in these patients...
  15. ncbi Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients
    Ambros J Beer
    Department of Nuclear Medicine, Technische Universitat Munchen, Germany
    J Nucl Med 46:1333-41. 2005
    ..Our aim was to study the kinetics and biodistribution of (18)F-Galacto-RGD in cancer patients...
  16. doi Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis
    Rebecca A Dumont
    Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
    J Nucl Med 52:1276-84. 2011
    ..The development of (68)Ga-RGD peptides would be of great utility given the convenience of (68)Ga production and radiolabeling, and (64)Cu-RGD peptides allow for delayed imaging with potentially improved tumor-to-background ratios...
  17. doi Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas
    Vladimir Evilevitch
    Abteilung Nuklearmedizin University of Freiburg, Freiburg, Germany
    Clin Cancer Res 14:715-20. 2008
    ..The aim of this study was to prospectively evaluate whether positron emission tomography with (18)F-fluorodeoxyglucose (FDG-PET) allows for a more accurate evaluation of histopathologic response...
  18. doi First clinical evidence that imaging with somatostatin receptor antagonists is feasible
    Damian Wild
    Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
    J Nucl Med 52:1412-7. 2011
    ..In this study, we evaluated whether imaging with sst antagonists was feasible in patients...
  19. doi Amyloid-β load predicts medial temporal lobe dysfunction in Alzheimer dementia
    Lars Frings
    Center of Geriatrics and Gerontology Freiburg, University Hospital Freiburg, Freiburg, Germany
    J Nucl Med 54:1909-14. 2013
    ..We aimed at elucidating the relationship between neocortical Aβ load, regional neuronal function, and memory impairment...
  20. doi Tumor cell metabolism imaging
    Christian Plathow
    Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany
    J Nucl Med 49:43S-63S. 2008
    ..In this review, we summarize recent data on the molecular mechanisms underlying the increased metabolic activity of cancer cells and discuss imaging techniques for studies of tumor glucose, lipid, and amino acid metabolism...
  21. doi Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100
    Franziska Leonhardt
    Department of Hematology and Oncology, FreiburgUniversity Medical Center, Albert Ludwigs University of Freiburg, Freiburg, Germany
    Blood 121:3307-18. 2013
    ..We identify negative regulation of GvHD-related neovascularization by miR-100, which indicates common pathomechanistic features of GvHD and ischemia...
  22. ncbi [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism
    Sabine Hellwig
    Department of Neurology, University of Freiburg, Germany
    Neurology 79:1314-22. 2012
    ....
  23. doi Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET
    H Christian Rischke
    Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany
    J Nucl Med 53:1352-8. 2012
    ..Furthermore, we assessed whether the genotypes of pheochromocytomas and paragangliomas correlate with the uptake of (18)F-DOPA...
  24. doi Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications
    Melpomeni Fani
    Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
    J Nucl Med 53:1481-9. 2012
    ..One may therefore generalize that somatostatin receptor 2 antagonists are sensitive to radiometal modifications and may preferably be coupled with a (68)Ga-NODAGA chelator-radiometal complex...
  25. ncbi Imaging of esophageal and gastric cancer
    Wolfgang A Weber
    Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany
    Semin Oncol 31:530-41. 2004
    ..Furthermore, quantitative measurements of tumor FDG uptake may predict histopathologic tumor response and patient outcome as early as 2 weeks after initiation of preoperative chemotherapy...
  26. ncbi Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, D 81675 Munich, Germany
    J Clin Oncol 22:900-8. 2004
    ....
  27. doi Imaging of tumor glucose utilization with positron emission tomography
    Andrea Buerkle
    Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany
    Cancer Metastasis Rev 27:545-54. 2008
    ....
  28. doi An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases
    Anca Ligia Grosu
    Department of Radiation Oncology, Albert Ludwigs Universitat Freiburg, Freiburg, Germany
    Int J Radiat Oncol Biol Phys 81:1049-58. 2011
    ..This study compares the uptake of FET and MET in gliomas and metastases, as well as treatment-induced changes. Furthermore, it evaluates the gross tumor volume (GTV) of gliomas defined on PET and magnetic resonance imaging (MRI)...
  29. doi 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma
    Benjamin Kasenda
    Department of Hematology Oncology, Freiburg University Medical Center, Freiburg, Germany
    J Nucl Med 54:184-91. 2013
    ..Primary central nervous system (CNS) lymphoma is an aggressive non-Hodgkin lymphoma with poor prognosis. We evaluated pretreatment (18)F-FDG PET as a prognostic marker in primary CNS lymphoma...
  30. doi PET for radiation treatment planning of brain tumours
    Anca L Grosu
    Department of Radiation Oncology, University of Freiburg, Germany
    Radiother Oncol 96:325-7. 2010
    ..The role of PET in the visualization of the biological characteristics of the tumours: proliferation (FLT-PET), hypoxia (FMISO-PET) and angiogenesis/peptide expression (RGD-PET) should be investigated in future studies...
  31. doi Hybrid imaging of peripheral skeletal disease by SPECT/high-resolution flat-panel CT
    Christian Lohrmann
    Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
    J Nucl Med 54:1323-6. 2013
    ..The aim of this study was to determine the impact of high-resolution cone-beam CT with flat-panel detectors on the interpretation of bone SPECT in diseases of the peripheral skeleton...
  32. doi [18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases
    Mate D Dobrossy
    Stereotactic Neurosurgery, Department of General Neurosurgery, University Freiburg Medical Center, Breisacher Str 64, 79106, Freiburg, Germany
    Nucl Med Biol 39:1077-80. 2012
    ..We explored the feasibility of [(18)F]DMFP-PET to image D2R availability in rat models of Huntington's (HD) and Parkinson's disease (PD)...
  33. doi Image quality and data quantification in dopamine transporter SPECT: advantage of 3-dimensional OSEM reconstruction?
    Oliver H Winz
    Department of Nuclear Medicine, University Hospital Aachen, Aachen, The Netherlands
    Clin Nucl Med 37:866-71. 2012
    ..We investigated if image reconstruction by 3-dimensional ordered-subset expectation maximization (3D-OSEM) with resolution recovery, which has recently become available for clinical routine, provides a relevant improvement...
  34. ncbi [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates
    Roland Haubner
    Department of Nuclear Medicine, Technische Universitat Munchen, 81675 Munchen, Germany
    Bioconjug Chem 15:61-9. 2004
    ..2 GBq of [18F]flouride. Moreover, the fast excretion, the suitable metabolic stability and the low estimated radiation dose allow to evaluate this tracer in human studies...
  35. doi Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients
    Werner Vach
    Clinical Epidemiology, Institute of Medical Biometry and Medical Informatics, Freiburg University Medical Center, Freiburg, Germany
    J Nucl Med 52:77S-85S. 2011
    ..Only if decision modeling does not allow definitive conclusions should randomized controlled trials be planned...
  36. pmc Activated platelets in carotid artery thrombosis in mice can be selectively targeted with a radiolabeled single-chain antibody
    Timo Heidt
    Department of Cardiology and Angiology, University of Freiburg, Freiburg, Germany
    PLoS ONE 6:e18446. 2011
    ....
  37. ncbi Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use
    Wolfgang A Weber
    Nuklearmedizinische Klinik, Klinikum rechts der Isar, Ismaning Strabetae 22, 81675 Munchen, Germany
    J Clin Oncol 21:2651-7. 2003
    ..To prospectively evaluate the use of positron emission tomography with the glucose analog fluorodeoxyglucose (FDG-PET) to predict response to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC)...
  38. doi [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma
    Sandra Purz
    Department of Nuclear Medicine, University of Leipzig, Liebigstrasse 18, 04103 Leipzig, Germany
    J Clin Oncol 29:3523-8. 2011
    ..The value of using FDG-PET to detect BM involvement has not been sufficiently defined. We compared the results of BMBs and FDG-PET for the diagnosis of BM involvement in a large pediatric group with HL...
  39. ncbi In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer
    Martin Behe
    Department of Nuclear Medicine, University Hospital Freiburg, 79106 Freiburg, Germany
    In Vivo 25:55-9. 2011
    ..The goal of the present study was to test the (177)Lu-labelled anti-PSMA monoclonal antibody 3/F11 ((177)Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model...
  40. doi Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B
    Philipp T Meyer
    Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany
    J Nucl Med 52:393-400. 2011
    ..We investigated the validity of relative regional CBF estimates (R(1)) gained from pharmacokinetic analyses of (11)C-labeled Pittsburgh compound B ((11)C-PIB) PET studies as a marker of neuronal activity and neurodegeneration...
  41. doi Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors
    Matthias R Benz
    Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, California, USA
    J Nucl Med 49:1038-46. 2008
    ..Knowledge of the interobserver variability of quantitative parameters is important in sarcomas as these tumors are frequently large and demonstrate heterogeneous (18)F-FDG uptake...
  42. ncbi Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma
    Martin Allen-Auerbach
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6942 USA
    Mol Imaging Biol 6:411-6. 2004
    ..We sought to determine whether integrated (hardware) fused PET/CT imaging results in further improvements in staging accuracy...
  43. pmc Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs
    Wolfgang A Weber
    Nuclear Medicine, University of Freiberg, Germany
    Nat Clin Pract Oncol 5:44-54. 2008
    ..Examples include imaging of the expression and inhibition of drug targets, noninvasive tissue pharmacokinetics, and early assessment of the tumor response...
  44. doi Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study
    Katja Ott
    Department of Surgery, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:2012-8. 2008
    ..The goal of the study was the definition of biologically different groups of patients prior to or early during induction therapy, with special emphasis on FDG non-avid tumors...
  45. ncbi Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome
    Joerg R Siewert
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Ann Surg 246:624-8; discussion 628-31. 2007
    ..To study the impact of induction chemotherapy on surgical risk and outcome in locally advanced Barrett cancer...
  46. ncbi O-(2-[(18)F]Fluoroethyl)- L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes
    Friederike C Rau
    Nuklearmedizinische Klinik der Technischen Universität München, Ismaninger Strasse 22, 81675 Munchen, Germany
    Eur J Nucl Med Mol Imaging 29:1039-46. 2002
    ..FET, in contrast, proved to be a specific tracer for differentiating between tumour-infiltrated and inflammatory LNs in the murine models studied...
  47. ncbi 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy
    Anca Ligia Grosu
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Int J Radiat Oncol Biol Phys 66:339-44. 2006
    ..To evaluate the role of 11C-methionine positron emission tomography (MET-PET) in target volume delineation for meningiomas and to determine the interobserver variability...
  48. ncbi Impact of animal handling on the results of 18F-FDG PET studies in mice
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Nucl Med 47:999-1006. 2006
    ..The aim of this study was to determine how these factors affect assessment of tumor glucose use by (18)F-FDG PET and to develop an imaging protocol that optimizes visualization of tumor xenografts...
  49. ncbi Chaperoning drug development with PET
    Wolfgang A Weber
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095 6942, USA
    J Nucl Med 47:735-7. 2006
  50. ncbi Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography
    Cecelia S Yap
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center Nuclear Medicine, UCLA School of Medicine, AR 144 CHS, Los Angeles, CA 90095 6948, USA
    Chest 129:393-401. 2006
    ....
  51. ncbi Molecular imaging in the development of cancer therapeutics
    Johannes Czernin
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Annu Rev Med 57:99-118. 2006
    ..We conclude with a proposal to integrate molecular imaging into the drug development process...
  52. ncbi Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer
    Jong Ho Kim
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095 6942, USA
    J Nucl Med 46:587-95. 2005
    ..The aim of this study was to compare PET with (18)F-FDG PET, in-line PET/CT, and software fusion of independently acquired CT and PET scans for staging of recurrent colorectal cancer (CRC)...
  53. ncbi Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients
    Barbara J Fueger
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, CA 90095 6942, USA
    Mol Imaging Biol 7:369-76. 2005
    ..This study was conducted to compare the clinical stage derived from 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) positron emission tomography (PET) to that of integrated PET/computed tomography (CT) in restaged breast cancer patients...
  54. ncbi Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study
    Benjamin S Halpern
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095 6942, USA
    J Nucl Med 46:603-7. 2005
    ..High photon attenuation and scatter in obese patients affect image quality. The purpose of the current study was to optimize lutetium orthosilicate (LSO) PET image acquisition protocols in patients weighing > or =91 kg (200 lb)...
  55. ncbi Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer
    Norbert Avril
    University of Pittsburgh Medical Center, Division of Nuclear Medicine, 200 Lothrop St, Pittsburgh, PA, 15213, USA
    J Clin Oncol 23:7445-53. 2005
    ....
  56. ncbi Use of PET for monitoring cancer therapy and for predicting outcome
    Wolfgang A Weber
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095 6942, USA
    J Nucl Med 46:983-95. 2005
    ..This review focuses on the practical aspects of (18)F-FDG PET for treatment monitoring and on how to perform a quantitative assessment of tumor (18)F-FDG uptake in clinical studies...
  57. ncbi Monitoring response to treatment in patients utilizing PET
    Norbert E Avril
    Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Radiol Clin North Am 43:189-204. 2005
    ..In the future, PET imaging can also serve in the evaluation of new therapeutic agents, new experimental treatments, and specifically in monitoring clinical phase II studies...
  58. ncbi Positron emission tomography for radiation treatment planning
    Anca Ligia Grosu
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University, Munich, Germany
    Strahlenther Onkol 181:483-99. 2005
    ..To evaluate the impact of positron emission tomography (PET) on target volume delineation for radiation treatment planning...
  59. ncbi Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction
    Katja Ott
    Department of Surgery, Technische Universitaet Muenchen, Ismaningerstr 22, D 81675, Munich, Germany
    J Clin Oncol 24:4692-8. 2006
    ..The aim of this study was to prospectively validate these findings by using an a priori definition of metabolic response...
  60. ncbi Monitoring cancer treatment with PET/CT: does it make a difference?
    Wolfgang A Weber
    Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California 90095, USA
    J Nucl Med 48:36S-44S. 2007
    ..The review concludes with an outlook on how PET/CT could make a difference in drug development and clinical management for patients...
  61. ncbi Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    Malik E Juweid
    Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 25:571-8. 2007
    ..To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials...
  62. ncbi Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET
    Christian Waldherr
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, David Geffen School of Medicine, University of California at Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095, USA
    J Nucl Med 46:114-20. 2005
    ..The aim of this study was to evaluate, whether PET with (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) may be used to monitor noninvasively the antiproliferative effects of tyrosine kinase inhibitors...
  63. ncbi Monitoring chemotherapy and radiotherapy of solid tumors
    Wolfgang A Weber
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095 6942, USA
    Eur J Nucl Med Mol Imaging 33:27-37. 2006
    ....
  64. ncbi Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience
    Anca Ligia Grosu
    Department of Radiation Oncology, Technical University Munich, Munich, Germany
    Int J Radiat Oncol Biol Phys 56:1450-63. 2003
    ..b) To validate the fully automatic CT/MET-PET image fusion technique with respect to accuracy and robustness. (c) To give a short glance at the clinical consequences for patients with brain tumors...
  65. ncbi Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia
    Katja Ott
    Department of Surgery, Klinikum rechts der Isar, Technical University Munich, Ismaningerstrasse 22, D 81675 Munich, Germany
    World J Surg 27:1035-9. 2003
    ..This finding strengthens the hypothesis that AEG I and AEG II are two different tumor entities...
  66. ncbi Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial
    Katja Ott
    Department of Surgery, Technische Universitä München, Munich, Germany
    J Clin Oncol 21:4604-10. 2003
    ..We prospectively evaluated the predictive value of therapy-induced reduction of tumor glucose use for subsequent response and patient survival in patients with gastric cancer treated by preoperative chemotherapy...
  67. ncbi Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells
    Martina Anton
    Institute of Experimental Oncology, Technische Universitat Munchen, Germany
    J Gene Med 6:119-26. 2004
    ..Its expression is almost exclusively restricted to the sympathetic nervous system. In this study we evaluated whether the NET can be used as a reporter gene for non-invasive imaging of genetically modified cells with radiolabeled probes...
  68. ncbi Brown adipose tissue and nuclear medicine imaging
    Wolfgang A Weber
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    J Nucl Med 45:1101-3. 2004
  69. pmc Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD
    Roland Haubner
    Nuklearmedizinische Klinik und Poliklinik, Technische Universitat Munchen, Germany
    PLoS Med 2:e70. 2005
    ..We developed [(18)F]Galacto-RGD, a (18)F-labeled glycosylated alphavbeta3 antagonist, allowing monitoring of alphavbeta3 expression with positron emission tomography (PET)...
  70. ncbi Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD
    Bernd J Pichler
    Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    J Nucl Med 46:184-9. 2005
    ..We studied a hapten-induced delayed-type hypersensitivity reaction (DTHR) as a model for inflammatory processes, since DTHRs are involved in many human autoimmune disorders...
  71. ncbi L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy
    Anca Ligia Grosu
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Int J Radiat Oncol Biol Phys 63:64-74. 2005
    ..The goal of this trial was to quantify the affect of MET-PET vs. with MRI in gross tumor volume definition for radiotherapy planning of high-grade gliomas...
  72. ncbi PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
    Florian Lordick
    Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
    Lancet Oncol 8:797-805. 2007
    ..We aimed to assess the feasibility of a PET-response-guided treatment algorithm and its potential effect on prognosis...
  73. ncbi Anesthesia and other considerations for in vivo imaging of small animals
    Isabel J Hildebrandt
    Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at the University of California, Los Angeles, CA 90095 6942, USA
    ILAR J 49:17-26. 2008
    ..Reproducible experimental conditions require clear, consistent reporting, in the study design and throughout the experiment, of the animal strain and gender, fasting, anesthesia, and how often individual animals were imaged...
  74. doi Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors
    Helen Su
    Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 35:1089-99. 2008
    ..In this study, we asked whether PET with [(18)F]gefitinib may be used to study noninvasively the pharmacokinetics of gefitinib in vivo and to image the EGFR status of cancer cells...
  75. ncbi Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture?
    Wolfgang A Weber
    Clin Cancer Res 13:3105-6. 2007
  76. ncbi Evaluation of insulin-like growth factor-1 in a mouse model of long-term abdominal radiation toxicity
    Carsten Nieder
    Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Anticancer Res 27:183-7. 2007
    ....
  77. doi Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma
    Liu Hua Wei
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Clin Cancer Res 14:3416-26. 2008
    ..The mechanisms underlying changes in metabolic activity were analyzed by measuring expression and functional activity of enzymes and transporters involved in the uptake of the studied imaging probes...
  78. doi Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas
    Matthias R Benz
    Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA
    J Nucl Med 49:1579-84. 2008
    ..The aim of this study was to determine whether combined assessment of tumor volume and metabolic activity improves the accuracy of (18)F-FDG PET for predicting histopathologic tumor response in patients with soft-tissue sarcomas...
  79. ncbi Positron emission tomography as an imaging biomarker
    Wolfgang A Weber
    Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095, USA
    J Clin Oncol 24:3282-92. 2006
    ..However, further prospective and randomized validation of PET is still required before PET controlled chemotherapy can be used in clinical practice...
  80. ncbi Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction
    Nicolaus Andratschke
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Int J Radiat Oncol Biol Phys 64:1513-8. 2006
    ..To test whether the clinically available growth factor erythropoietin (EPO) influences radiation-induced normal-tissue damage in a model of kidney dysfunction...
  81. ncbi Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion
    Benjamin S Halpern
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, AR 128 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095 6942, USA
    Chest 128:2289-97. 2005
    ..To compare the diagnostic accuracy of positron emission tomography (PET) and integrated PET/CT and to evaluate the performance of software fusion for staging of non-small cell lung cancer (NSCLC)...
  82. ncbi Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy
    Anca L Grosu
    Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675 Munich, Germany
    Int J Radiat Oncol Biol Phys 63:511-9. 2005
    ..To develop a valid treatment strategy for recurrent high-grade gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide...
  83. pmc Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
    Derek W Bartlett
    Chemical Engineering, California Institute of Technology, 1200 East California Boulevard, MC 210 41, Pasadena, CA 91125, USA
    Proc Natl Acad Sci U S A 104:15549-54. 2007
    ..Optimization of internalization may therefore be key for the development of effective nanoparticle-based targeted therapeutics...